A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension

You may be able to join if

• Participants: Participants who completed the double-blind study intervention treatment during Study 206713 or Study 213744.
• Age: Adults and adolescents ≥12 years of age, at the time of signing the informed consent/assent. [For countries where local regulations or the regulatory status of study medication permits enrolment of adults only, participants recruited will be ≥18 years of age]. Note: German and UK Participants: In Germany and UK only adult participants (≥18 years) are to be included in this clinical trial.
• Male or eligible female • Female Participants: • A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: o Is a woman of non-childbearing potential (WONCBP) as defined in Section 10.4.1 of the protocol OR o For all woman of childbearing potential (WOCBP) continuation of highly effective contraceptive method ( with a failure rate of <1%, as described in Section 10.4.2 of the protocol) is required between the prior study and enrolment into this study without any interruptions and must continue during the study intervention period and for at least 30 weeks after the last dose of study intervention. • A WOCBP must have a negative highly sensitive urine pregnancy test at Visit 1 prior to receiving first dose. Additional requirements for pregnancy testing during and after study intervention are located in Section 8.2.5. of the protocol •If highly effective contraceptive method was interrupted prior to enrolment into this study, the reason for interruption must be discussed with medical monitor and the following must be done: o Highly effective contraceptive method must be restarted and continued for at least 14 days prior to first dose • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. • The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated in relationship to the first dose of study intervention). The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. Note: If the childbearing potential changes after start of the study (e.g., a premenarcheal female participant experiences menarche) or the risk of pregnancy changes (e.g., a female participant who is not heterosexually active becomes active), the participant must discuss this with the investigator, who should determine if a female participant must begin a highly effective method of contraception. If reproductive status is questionable, additional evaluation should be considered
• Informed Consent: Capable of giving signed informed consent/assent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. French participants: In France, a participant will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.